Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDECT: 124I-cG250 PET/CT for Renal Cell Carcinoma
NCT00606632Phase 3Completed
- Sponsor
- Heidelberg Pharma AG
- Start
- Mar 2008
- Primary completion
- Nov 2009
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Girentuximab I-124 in renal cell carcinoma (RCC), sponsored by Heidelberg Pharma AG. Primary endpoints: Sensitivity of 124I-cG250 PET/CT Versus Diagnostic CT at 6 months and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT at 6 months. Started Mar 2008; status: completed.
02
Drugs
Girentuximab I-124
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00606632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00606632.